CA-YOU.COM
6.3.2024 02:17:34 CET | Business Wire | Press release
You.com announces its designation as one of the few new default browser options on iOS 17.4 for European Union users, alongside significant updates to its AI-powered mobile browsing app, You.com AI Search and Browse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305667601/en/
Newly Revamped You.com AI Search and Browse App Now Available on iOS 17.4 in the European Union as Part of New Browser Choice Screen (Graphic: Business Wire)
The inclusion in the iOS browser choice screen today highlights You.com's increasing global popularity and dedication to delivering a cutting-edge AI-powered web search and browsing experience loved by its users.
“We're excited to share the latest update to our You.com AI Search and Browse app, now available as a default browser choice on iOS 17.4 for users throughout the European Union. As the only AI chat-native browser option on the new EU browser choice screen for iOS, You.com is setting a new standard for what a browser can do thanks to AI,” said Richard Socher, CEO of You.com.
Socher continued: “With the introduction of 'Ask AI' and a fresh, intuitive app design, we're not just updating features, we're enhancing how you find information online. You.com is more than another way to search and browse — it's an AI Assistant designed to make you more productive, creative, and extraordinary. We invite you to make You.com your default browser for a smarter way to find answers.”
What’s new:
- Introducing “Ask AI”: Dive into the future of search with our new "Ask AI" feature, delivering AI-powered answers complete with citations for a more informative and trustworthy browsing experience.
- A fresh, updated experience: Enjoy a cleaner, more intuitive interface with our updated app design, making navigation smoother and more enjoyable than ever before.
- Enhanced mobile homepage: Discover what's trending with an improved mobile home page that now offers trending suggestions, keeping you informed and engaged with the latest and most relevant content.
With You.com, users can say goodbye to endless scrolling through blue links and tedious websites. Search alone is inefficient for in-depth research, and ineffective at answering complex, multi-step questions. A conversational search experience powered by cutting-edge AI, You.com delivers immediate, comprehensive answers across any topic, supplemented by follow-up suggestions for deeper exploration.
You.com enhances the efficiency of finding information and enriches the quality of results with advanced AI functionalities that support text generation, content summarization, image creation, and more. You.com stands out for its powerful AI Modes, from its Research Mode which can browse and synthesize information from multiple websites simultaneously with extensive citations to its Genius Mode capable of multi-step complex problem solving.
Whether users prefer traditional search methods or the enriched, AI-enhanced search, You.com offers seamless management of searches, chats, and visited websites, with easy options for saving or deleting history. Linked citations further empower users to verify responses and delve into sources, ensuring a trustworthy and comprehensive browsing experience.
You.com also prioritizes privacy, offering ad-blocking, pop-up blocking, and tracking protection capabilities.
Download You.com today for free and experience a better way to search.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305667601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom